Impact of CYP2D6 Genetic Polymorphisms on the Vulnerability to Drug-drug Interactions With Tramadol

NCT ID: NCT04249674

Last Updated: 2022-01-19

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 172 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-11-04
• Study Completion Date: 2022-12-31

Brief Summary

Despite its poor abundance in the liver, CYP2D6 is the second most important CYP in drug metabolism, metabolizing 20% of drugs. The high inter-individual variability in CYP2D6 expression is explained by genetic variations, but also by drug-drug interactions (DDIs). Recent studies have pointed out the poor therapeutic predictable value of DDI. Indeed, the clinical outcomes of a DDI may involve several intrinsic factors affecting the vulnerability to and extent of DDI, such as genetic polymorphisms, comorbidities, age and sex.

In this regard, the present research project aims to investigate the effect of genetic polymorphism on DDIs involving CYP2D6 (gene-environment interaction) and its implications for tramadol efficacy and safety in a clinical setting. In a previous study, we demonstrated differences in both the rate of phenoconversion and the magnitude of DDI in healthy volunteers, that were either heterozygote normal metabolizers (NMs) carrying a non-functional CYP2D6 allele (activity score (AS) 1) and homozygous NM carrying two fully-functional CYP2D6 alleles (AS 2).

This prospective study will include patients scheduled for a general surgery of less than 3 hours and planned to be treated with oral tramadol as a routine post-operative pain management.

Patients taking part in the study may receive diagnosis, therapeutic or other interventions but the groups of individuals (controls vs inhibited) are predefined based on the routine treatment of the patients.

There will be no assigned specific interventions to the study participants and CYP2D6 phenotypes will be classified in five activity score groups (0.5, 1, 1.5, 2, >2) in the absence or presence of a potent CYP2D6 inhibitor received as part of routine medical care.

PK of tramadol and its active metabolite (M1), as well as its analgesic and PD effects and safety, will be compared between groups. Finally, the data generated will be used to build a physiologically-based PK (PBPK) model for tramadol in different sub-groups. The model will aim to predict the effect of CYP2D6 inhibition in virtual populations with different genetically-related CYP2D6 activities. This should allow prospective dose adjustment of tramadol (or appropriate drug selection) based on patients' genotype in the presence of a CYP2D6 inhibitor.

Conditions

Interaction; Pain

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Patient under a CYP2D6 inhibitor and under Tramadol

Dextrometorphan

Intervention Type: DIAGNOSTIC_TEST

Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)

Genotyping by single nulcetoide polymorphism.

Intervention Type: GENETIC

Single nucleotide polymorphism determination

Patient not under a CYP2D6 inhibitor but under Tramadol

Dextrometorphan

Intervention Type: DIAGNOSTIC_TEST

Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)

Genotyping by single nulcetoide polymorphism.

Intervention Type: GENETIC

Single nucleotide polymorphism determination

Interventions

Dextrometorphan

Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)

Intervention Type: DIAGNOSTIC_TEST

Genotyping by single nulcetoide polymorphism.

Single nucleotide polymorphism determination

Intervention Type: GENETIC

Eligibility Criteria

Inclusion Criteria

• Any male and female patients > 18 years scheduled for a surgery of less than 3 hours duration and planned to be treated with oral tramadol as a routine management of post-operative pain;
• Patients with physical conditions classified as ASA I to III, based on American Society of Anesthesiology classification;
• Patients treated chronically with a potent CYP2D6 inhibitor (for CYP2D6-inhibited arms only);
• Understanding of French language and able to give a written inform consent

Exclusion Criteria

• Pregnant or breastfeeding woman
• Any pathologies, use of drugs or food that may affect CYP activity (for control arms only and based on the 'drug interactions and cytochromes P450' table published by The Service of clinical Pharmacology and Toxicology [3], HUG and on the investigator's knowledge)
• Liver transplantation history
• Sensitivity to dextromethorphan (CYP2D6 probe drug) or any contra-indication to dextrometorphan
• Medical history of cirrhosis (Child Pugh B and C) or/and hepatosteatosis.
• Glomerular filtration rate (GFR) < 30 ml/min/1.73m2

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Youssef Daali

UNKNOWN

Sponsor Role: collaborator

Jules Desmeules

UNKNOWN

Sponsor Role: collaborator

Kenza Abouir

UNKNOWN

Sponsor Role: collaborator

Eduardo Schiffer

UNKNOWN

Sponsor Role: collaborator

Bernard Walder

UNKNOWN

Sponsor Role: collaborator

University Hospital, Geneva

OTHER

Sponsor Role: lead

Responsible Party

Caroline Samer

Doctor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Youssef Daali, Pr.

Role: STUDY_DIRECTOR

University Hospital, Geneva

Caroline Samer, Doctor

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Geneva

Locations

Geneva University Hospitals, HUG

Geneva, , Switzerland

Site Status: RECRUITING

Countries

Switzerland

Central Contacts

Caroline Samer, Doctor

Role: CONTACT

caroline.samer@hcuge.ch

022 372 99 47

Facility Contacts

Caroline Samer, Dr

Role: primary

caroline.samer@hcuge.ch

Kenza Abouir

Role: backup

kenza.abouir@hcuge.ch

Other Identifiers

2019-01418

Identifier Type: -

Identifier Source: org_study_id